Home > Insider Trading > Filing (0001144204-12-026006)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
895051	Entremed Inc	ENMD	Biological Products, (No Disgnostic Substances) (2836)	581959440

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1542073	Wei-Wu He	Entremed, Inc. 9640 Medical Center Drive Rockville MD 20850		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2012-05-01	441,072	$0.00	441,072	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Warrants (Right to Buy)	Acquisiton	2012-01-20	86,957	$0.00	86,957	$1.40

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
86,957	2012-07-29	2017-07-29	No	5	A	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	24,698	Direct

Footnotes

Reflects the conversion price of a certain Subordinated Mandatorily Convertible Note ("Convertible Note") acquired in connection with the Company's strategic financing entered into on January 20, 2012 ("Strategic Financing"). The Convertible Note automatically converts into shares of common stock, at the conversion price of $1.15, upon stockholders approval of the Strategic Financing. The conversion price reflects the 10-day average closing sale price of the Company's Common Stock ending on January 20, 2012. The stockholders approved the Strategic Financing at the Company's Annual Stockholders Meeting held on April 30, 2012 ("2012 Annual Meeting").
Held indirectly by Emerging Technology Partners LLC.
Warrants were acquired in connection with the Strategic Financing and become exercisable at any time on or after 90 days following the 2012 Annual Meeting.